- Conditions
- Alzheimer Disease
- Interventions
- xaliproden (SR57746A)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 10,856
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Placebo, Pembrolizumab
- Other · Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Interventions
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more
- Conditions
- Cervical Disc Disease
- Interventions
- BAGUERA®C Cervical Disc Prosthesis, Mobi-C Cervical Disc
- Device
- Lead sponsor
- Spineart USA
- Industry
- Eligibility
- 22 Years to 69 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 23 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 233
- States / cities
- Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
- Conditions
- Persistent Atrial Fibrillation
- Interventions
- Sphere-9™ Catheter and Affera™ Ablation System
- Device
- Lead sponsor
- Medtronic Cardiac Ablation Solutions
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Atlanta, Georgia + 11 more
- Conditions
- HIV-1 Infections
- Interventions
- Raltegravir, Darunavir/Ritonavir
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Lung Cancer
- Interventions
- MEDI4736, tremelimumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Interventions
- Infliximab and Basiliximab
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 6 Months to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Columbus, Ohio • San Antonio, Texas
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, fulvestrant
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 205
- States / cities
- Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 127 more
- Conditions
- Keratoconus and Ectasia
- Interventions
- Riboflavin, VEGA UV-A Illumination System
- Drug · Device
- Lead sponsor
- Topcon Medical Systems, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 7 more
- Conditions
- Generalized Lipodystrophy
- Interventions
- Metreleptin
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 4 more
- Conditions
- Smoking Cessation, Vaping Cessation
- Interventions
- Cytisinicline
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Neonatal Encephalopathy, Birth Asphyxia
- Interventions
- Normal saline placebo, Erythropoietin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more
- Conditions
- Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
- Drug
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- monoclonal antibody 11D10 anti-idiotype, monoclonal antibody 3H1 Alu Gel
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 75
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
- Conditions
- Healthy Subject, Tobacco Use Disorder
- Interventions
- Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
- Other · Dietary Supplement
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Magnetic Resonance Imaging, Oxaliplatin, Surgical Procedure
- Procedure · Drug
- Lead sponsor
- Arjun Mittra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Dallas, Texas
- Conditions
- Huntington Disease, Lewy Body Disease
- Interventions
- Treadmill Walking
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 37
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 31 more
- Conditions
- Limb-girdle Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Interventions
- Capecitabine, Celecoxib, Radiation Therapy, Placebo
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 13
- States / cities
- Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more